COPD

The distribution of phenotypes in a population of SEVERE COPD

Koblizek V, Zatloukal J, Plutinsky M, Safranek P, Novotna B, Kocova E, Hejduk K, et al.
Czech Multicentre Research Database of COPD Group

Disclosures

- **No relevant disclosures to be made, related to this project**

- Support by a research grant of **The Czech Ministry of Health** 15/14/NAP and by research grants from: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Medicom, Novartis and Takeda

- The Project is endorces by **The Czech Pneumological Society**
- The Project is monitored by CZ **State Institute for Drug Control**
- Technological and analytical background and project management is provided by the **Institute of Biostatistics and Analyses**, Masaryk University, Brno, CZ

Objectives

- COPD - heterogeneous syndrome
- Czech Multicentre Research Database of COPD
- Methods
- Clinical phenotypes evaluation
- Results
- Conclusion

COPD - heterogenous syndrome

Global guidelines

GOLD STRATEGY 2011-2014

ERS/ATS/ACCP 2011
ERS/ATS 2005

Local guidelines

CANADIAN 2007 pre-phenotypic

CELLI 2008 REHAB + BODE

NICE, INDIA 2012,2013 EBM guidelines

SPAIN 2012 1st phenotypic approach

Czech 2013 GOLD + phenotypic


AMERICAN JOURNAL OF Respiratory and Critical Care Medicine®
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on June 3, 2010, doi:10.1164/rccm.200912-1843CC
American Journal of Respiratory and Critical Care Medicine Vol 182. pp. 598-604, (2010)

doi: 10.1164/rccm.200912-1843CC

Clinical Commentary

Chronic Obstructive Pulmonary Disease Phenotypes

The Future of COPD

MeiLan K. Han[1], Alvar Agusti[3], Peter M. Calverley[4], ...me R. Celli[5], Gerard Criner[6], Jeffrey L. Curtis[1,7], ... Fabbri[8], Jonathan G. Goldin[9], Paul W. Jones[10], ...[11], Barry J. Make[12], Klaus F. Rabe[13], ...[14], Frank C. Sciurba[15], ...[16], Jorgen Vestbo[17], George R. Washko[5], ...nd Fernando J. Martinez[2]

This Article
Full Text
Full Text (PDF)
All Versions of this Article: 200912-1843CCv1 182/5/598 most recent
Alert me when this article is cited
Alert me if a correction is posted

Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journa
Download to citation manager
Get Permissions

Citing Articles
Citing Articles via HighWire

Google Scholar
Articles by Han, M. K.
Articles by Martinez, F. J.

PubMed
PubMed Citation
Articles by Han, M. K.
Articles by Martinez, F. J.

Czech Multicentre Research Database of COPD



- Observational Multicentre Prospective Study
- Consecutive severe COPD patients
- Assessment of mortality in relation to the phenotypes
- Inclusion - postBD $FEV_1 \leq 60$ %
  - definite clinical diagnosis of COPD
  - ≥ 8 weeks free of exacerbation
- Exclusion - asthma or bronchiectasis without COPD, cystic fibrosis, end-stage of COPD or malignancy, immobility

Novotna et al Int J Chron Obstruct Pulmon Dis accepted 2014

Methods

Appointment type	*Baseline appointment (stable COPD)*	*Planned appointment (stable COPD)*	*Emergency appointment (emergency hospitalization)*	
Appointment interval	*Registry enrollment*	*Every 6 months*	*In the event of emergency hospitalization (NOT planned hospitalization)*	*End of study*
Appointment number	*1.*	*2. - 11.*	*E1, E2, E3, etc.*	
Informed consent	**X**			
Patient history	**X**	**X**		
Demographic data	**X**			
Risk factors	X	X		
Symptoms (CAT, mMRC*)**	**X**	**X**		
Quality of life (SGRQ)	X	X		
Current medications	**X**	**X**		
Physical examination	**X**	**X**		
ECG	X	X*		
Laboratory test (A1AT)	X			
Frequency of exacerbations	**X**	**X***		
Nasal symptoms (SNOT 22)***	**X**	**X***		
Lung function	**X**	**X**		
Arterial blood gases	X	X		
6MWT***	**X**	**X**		
Pedometer (ADL°)	X	X*		
Depression questionnaires	X	X		
Chest HRCT	X	X§		
Echocardiography	X	X**		
DEXA	X			
Skinfold anthropometry	X	X*		
Compliance assessment	X	X*		
Blood sample (-70°C) – genomic analysis	X			
Reason for sudden hospital admission			X	
Patient progress during admission			X	
Patient self-withdrawal from study				X
Cause of death				**X**
5 year survival				X

Novotna et al Int J Chron Obstruct Pulmon Dis accepted 2014

Clinical phenotypes evaluation

- *Subjective evaluation*

  Physician´s on site conclusion

Clinical phenotypes evaluation

- *Subjective evaluation*

  Physician´s on site conclusion

- Objective evaluation

  Subsequent PC analysis of all DATABASE parameters



definite emphysema with bronchiectasis



Koblizek et al. Biomed Pap 2013



Koblizek et al. Biomed Pap 2013



Diagnosis of COPD
(post-BD spirometry)

Sputum production
≥ 3M/12M (≥ 2 years)

yes

no

Long–asting excessive daily production of
mucopurulent sputum with blood traces

yes

Chest CT with presence
of bronchiectasis §

yes

no

no

COPD + bronchiectasis phenotype

Bronchitic phenotype

*Emphysematous phenotype **

BMI < 21 ** and visible
atrophy of muscles
(no other cachexia cause)

yes

Pulmonary cachexia phenotype

Acute exacerbation
≥ 2 years

yes

Frequent-exacerbation phenotype

++BDT,+BCT, ↑FeNO,
↑eo, history of asthma
history of atopy,↑IgE, +BDT

yes

*COPD + asthma phenotype ****

Koblizek et al. Biomed Pap 2013



Koblizek et al. Biomed Pap 2013



Koblizek et al. Biomed Pap 2013



Koblizek et al. Biomed Pap 2013

Results

preliminary *analysis of baseline data related to clinical phenotypes*



Demografic data

Gender	Female	**43** (22.6%)
	Male	**147** (77.4%)
Age		**67.0** (55.0; 78.0)
BMI (kg/m2)		**27.2** (18.6; 36.8)
Post BD FEV_1 (%)		**42.0** (24.6; 58.7)
Smoking status	Ex-smoker	139 (**73.2%**)
	Non-smoker	16 (**8.4%**)
	Current moker	35 (**18.4%**)
Duration of COPD before enrollment (yrs)		**8.1** (0.3; 23.8) N=179
Total education time (yrs)		**12.0** (9.0; 18.0) N=143
Total numer of acute exacerbation/year		**0.0 (0.0; 4.0)** N=188
GOLD categories	A	11 (**5,8%**)
	B	38 (**20.0%**)
	C	22 (**11,5%**)
	D	119 (**62.7%**)

N = 190 (Aug 2013-Feb 2014)

Flow-chart of **phenotypical analysis** of patients with **severe COPD**



Clinical phenotypes
in subjects with SEVERE COPD

COPD phenotype	„Subjective“	„Objective“	P-value
Bronchitic	77 (53.1 %)	87 (**60.0 %**)	0.076
Emfyzematic	96 (66.2 %)	111 (**76.6 %**)	0.06
ACOS	17 (11.7 %)	5 (**3.4 %**)	**0.002**
Frequent exacerbation - AE	36 (24.8 %)	45 (**31.0 %**)	1.00
Pulmonary cachexia	14 (9.7 %)	22 (**15.2 %**)	**0.021**
COPD/BE	5 (3.4 %)	36 (**24.8 %**)	**< 0.001**

N = 145

Combinations of **objectively evaluated** COPD phenotypes



Total 93 *(64.1 %)*

N = 145

Combinations of **objectively evaluated** COPD phenotypes



N = 145

Venn diagram for **objectively evaluated** phenotypes



COPD

Proportional Venn diagram for **objectively evaluated** phenotypes ***Frequent exacerbators***



N = 145

Proportional Venn diagram for **objectively evaluated** phenotypes ***ACOS***



N = 145

Proportional Venn diagram for **objectively evaluated** phenotypes ***Pulmonary cachexia***



N = 145

Symptoms and phenotypes

Parameter		Bronchitic (N = 87)	Emphysematic (N = 111)	ACOS (N = 5)	Exacerbators (N = 45)	Cachexia (N = 22)
mMRC		2,0 (0,0; 4,0)	2,0 (0,6; 4,0)	2,0 (1,0; 2,0)	2,0 (0,3; 4,0)	**2,5 (0,2; 4,0)**
fatigue		38 (43,7 %)	44 (39,6 %)	2 (40,0 %)	**22 (48,9 %)**	**11 (50,0 %)**
SNOT	ENT symptom	19,0 (0,8; 48,2)	18,0 (4,0; 52,3)	25,0 (14,0; 36,0)	**27,0 (1,3; 52,0)**	25,0 (0,7; 75,0)
CAT	caugh	2,0 (1,0; 4,8)	2,0 (0,2; 4,0)	2,0 (1,0; 3,0)	**3,0 (1,0; 4,7)**	2,0 (1,0; 4,0)
	phlegm	**3,0 (1,0; 5,0)**	2,0 (1,0; 4,0)	2,5 (1,0; 4,0)	**3,0 (1,0; 5,0)**	2,5 (1,0; 4,0)
	ch.tightness	1,0 (0,0; 3,0)	1,0 (0,0; 3,8)	1,5 (1,0; 3,0)	1,0 (0,0; 4,7)	**2,0 (0,0; 4,0)**
	shortness of b.	3,5 (0,0; 5,0)	3,0 (1,0; 5,0)	2,5 (0,0; 3,0)	**4,0 (0,3; 5,0)**	**4,0 (1,0; 5,0)**
	limitation	1,0 (0,0; 5,0)	1,0 (0,0; 5,0)	0,5 (0,0; 1,0)	2,0 (0,0; 4,7)	**3,0 (1,0; 5,0)**
	sleep	1,5 (0,0; 4,0)	2,0 (0,0; 4,8)	0,5 (0,0; 2,0)	2,0 (0,0; 5,0)	**2,5 (0,0; 5,0)**
	energy	2,5 (1,0; 5,0)	2,0 (1,0; 5,0)	2,0 (2,0; 3,0)	**3,0 (0,3; 5,0)**	**3,0 (1,0; 5,0)**
CAT	overall score	17,5 (6,8; 34,5)	18,0 (6,0; 33,2)	13,5 (9,0; 18,0)	**20,0 (8,6; 35,4)**	**21,0 (13,0; 34,0)**
SGRQ	T	48,6 (16,8; 75,2)	50,2 (18,2; 77,8)	42,4 (31,0; 44,6)	**55,8 (26,4; 87,1)**	**58,0 (27,0; 87,7)**
	I	38,0 (5,9; 72,4)	38,7 (10,0; 73,0)	38,0 (17,9; 38,2)	48,4 (18,9; 80,9)	**51,6 (14,1; 78,3)**
	A	66,2 (20,3; 92,7)	66,2 (26,1; 92,8)	47,2 (0,0; 48,3)	67,1 (29,0; 100,0)	**72,4 (25,0; 100,0)**

N = 145

Comorbidities and phenotypes

Parameter	Bronchitic (N = 87)	Emphysematic (N = 111)	ACOS (N = 5)	Exacerbators (N = 45)	Cachexia (N = 22)
cardiac failure	**14 (16,1 %)**	10 (9,0 %)	0 (0,0 %)	5 (11,1 %)	1 (4,5 %)
atrial fibrillation	**12 (13,8 %)**	11 (9,9 %)	0 (0,0 %)	5 (11,1 %)	1 (4,5 %)
diabetes	**17 (19,5 %)**	13 (11,7 %)	0 (0,0 %)	8 (17,8 %)	0 (0,0 %)
depression	14 (16,1 %)	22 (19,8 %)	0 (0,0 %)	**11 (24,4 %)**	4 (18,2 %)
osteoporosis	9 (10,3 %)	15 (13,5 %)	1 (20,0 %)	7 (15,6 %)	3 (13,6 %)
sleep apnea	**6 (6,9 %)**	5 (4,5 %)	0 (0,0 %)	2 (4,4 %)	0 (0,0 %)
beta-blockers	22 (25,3 %)	25 (22,5 %)	2 (40,0 %)	7 (15,6 %)	4 (18,2 %)
statins	**25 (28,7 %)**	27 (24,3 %)	0 (0,0 %)	8 (17,8 %)	6 (27,3 %)

N = 145

Exams, PFT and depression in phenotypes

Parameter	Bronchitic (N = 87)	Emphysematic (N = 111)	ACOS (N = 5)	Exacerbators (N = 45)	Cachexia (N = 22)
heart rate	84,0 (64,4; 110,6)	87,0 (65,2; 111,0)	87,0 (70,0; 92,0)	86,0 (64,6; 114,4)	**88,0 (55,2; 114,8)**
respir.rate	18,0 (12,0; 27,6)	18,0 (12,0; 28,0)	18,0 (16,0; 22,0)	18,0 (11,3; 27,4)	**20,0 (12,4; 28,0)**
FEV_1 (%)	43,9 (24,4; 57,8)	43,0 (25,0; 58,0)	51,0 (39,7; 60,0)	40,0 (22,5; 58,7)	**38,5 (22,8; 56,0)**
FVC (%)	70,9 (41,2; 96,2)	74,5 (46,5; 103,6)	77,0 (64,9; 100,0)	73,0 (43,8; 109,0)	76,2 (51,6; 108,5)
RV (%)	183,0 (113,0; 276,6)	201,0 (118,8; 276,4)	145,0 (109,0; 221,0)	201,0 (121,5; 276,7)	**219,0 (150,0; 274,0)**
IC/TLC (%)	30,0 (17,6; 70,7)	27,0 (16,0; 68,5)	34,0 (31,2; 50,0)	27,0 (16,0; 46,4)	**24,0 (16,0; 94,4)**
DLCO (%)	46,0 (23,9; 87,6)	41,5 (20,5; 77,0)	55,5 (35,0; 68,0)	43,0 (23,4; 72,8)	**31,0 (10,3; 54,4)**
Kco (%)	62,0 (28,9; 116,0)	55,0 (24,2; 91,7)	62,0 (41,0; 104,0)	56,0 (25,0; 89,0)	**40,0 (11,3; 67,0)**
Zung's scale	53,0 (35,0; 69,0)	51,5 (31,5; 68,8)	54,0 (45,0; 58,0)	51,0 (35,0; 69,1)	**56,0 (29,0; 75,0)**
Beck's scale	6,5 (1,0; 15,9)	6,0 (1,0; 15,0)	6,0 (4,0; 7,0)	7,0 (1,4; 15,9)	**8,0 (0,0; 18,0)**

N = 145

Proportional Venn diagram for **objectively evaluated** phenotypes ***COPD + BE***



N = 145

COPD/BE and non-BE COPD

Parameter	Specification	non-BE COPD	COPD/BE	P-value
postBD FEV1	%	43.9	42.7	0.55
Kco	%	61.0	60.0	0.92
RV	%	190	193	0.89
IC/TLC	**%**	**30.5**	**24.5**	**0.04**
WA mean	**%**	**71.92**	**70.11**	*0.06*
LAA total	**%**	**9**	**13**	**0.05**
mucus plugs	small airways	8.6	13.9	1.0
mucus plugs	large airways	7.6	13.9	1.0
diabetes	yes (%)	19	13.9	0.48
CAD	yes (%)	26.7	30.6	0.65
heart failure	**yes (%)**	**12.4**	**25**	*0.07*
osteoporosis	yes (%)	9.5	13.9	0.53

N = 145

Conclusion

- The clinical presentation of severe COPD varies widely among patients

Conclusion

- The clinical presentation of severe COPD varies widely among patients
- „Subjective“ and „Objective“ phenotypes can differ



Conclusion

- Individual clinical presentation of severe COPD varies widely
- „Subjective“ and „Objective“ phenotypes can differ
- 2/3 of severe COPD subjects had two or more phenotypes



COPD

Acknowledgments

Vytrisalova, K. Neumannova, A. Vlachova, M. Marel, M. Majerciakova, P. Musilova, B. Snelerova, P. Popelkova, R. Praus, M. Kopecky, L. Pavlikova, T. Dvorak, L. Heribanova, T. Vencalek, K. Hejduk, J. Jarkovsky, J. Svancara, M. Hronek, M. Kovarik, N. Pauk (Hradec Kralove, Olomouc, Brno, Plzen, Praha, Zlin, Jihlava, Usti nad Labem, Ostrava, Liberec, Hradec Králové, Czech Republic)

http://clinicaltrials.gov/ct2/show/NCT01923051
http://chopn.registry.cz/index-en.php

email: vladimir.koblizek@fnhk.cz